4 Healthcare Stock Stories for Thursday Investment Wellness

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Biogen IDEC (NASDAQ:BIIB): Closing price $216.00

Biogen posted first-quarter earnings per share of $1.96, which was well above the Zacks Consensus Estimate of $1.57 and a 41 percent increase from the year-ago quarter. First quarter 2013 revenues rose by 10 percent to $1.415 billion, above the Zacks Consensus Estimate of $1.387 billion, with gains driven by Avonex and Tysabri. What is more, earnings were raised by roughly 17 cents thanks to a lower tax rate; if one-time items are counted, first quarter 2013 earnings increased by 43 percent to $1.79 per share.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BIIB

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business